Sanofi Pasteur's Typhoid Vi polysaccharide vaccine

COMBINATION_PRODUCT3 trials

Sponsors

GlaxoSmithKline

Conditions

DiarrhoeaSalmonella InfectionsTyphoid Fever

Phase 1

A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants

CompletedNCT05073003

GlaxoSmithKlineDiarrhoea

Start: 2021-10-06End: 2025-06-24Updated: 2025-12-04

A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever

CompletedNCT05480800

GlaxoSmithKlineSalmonella Infections

Start: 2022-09-13End: 2025-01-07Updated: 2025-11-28

Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults

CompletedNCT05613205

GlaxoSmithKlineTyphoid Fever

Start: 2022-11-28End: 2024-04-02Updated: 2025-01-24

Related Papers

Safety and immunogenicity of a conjugate vaccine candidate against Salmonella enterica serovars Typhi and Paratyphi A in healthy adults in Europe: a phase 1 randomised controlled trial.

2026-01-23

Safety and Immunogenicity of a 4-Component Generalized Modules for Membrane Antigens <i>Shigella</i> Vaccine in Healthy European Adults: Randomized, Phase 1/2 Study

The Journal of Infectious Diseases2024-06-1020 citations

Putative correlates of protection against shigellosis assessing immunomarkers across responses to S. sonnei investigational vaccine.

2024-03-087 citations